| Title |
Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids
|
|---|---|
| Published in |
Drugs, September 2017
|
| DOI | 10.1007/s40265-017-0812-3 |
| Pubmed ID | |
| Authors |
Karly P. Garnock-Jones, Sean T. Duggan |
| Abstract |
Oral ulipristal acetate (Esmya(®); Fibristal(®)), a synthetic selective progesterone receptor modulator, is the first selective progesterone modulator to be approved for the treatment of uterine fibroids. It was initially approved for the preoperative treatment of moderate to severe uterine fibroid symptoms in women of reproductive age. Recently, the indication was extended in the EU to include the intermittent treatment of moderate to severe uterine fibroid symptoms. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the preoperative and intermittent use of ulipristal acetate in patients with symptomatic uterine fibroids. Ulipristal acetate is an effective and generally well tolerated treatment for patients with symptomatic uterine fibroids, both as preoperative, single-course treatment and as intermittent, longer-term treatment. It is noninferior in efficacy to intramuscular leuprolide acetate, as a preoperative treatment, and is associated with a lower rate of hot flashes, a common adverse event with gonadotropin-releasing hormone analogues. Thus, ulipristal acetate is an effective option for both preoperative and intermittent treatment of moderate to severe, symptomatic uterine fibroids in women of reproductive age. |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 44 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 18% |
| Student > Bachelor | 5 | 11% |
| Student > Postgraduate | 4 | 9% |
| Professor > Associate Professor | 4 | 9% |
| Student > Master | 3 | 7% |
| Other | 5 | 11% |
| Unknown | 15 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 11% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Agricultural and Biological Sciences | 1 | 2% |
| Nursing and Health Professions | 1 | 2% |
| Other | 2 | 5% |
| Unknown | 18 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 September 2023.
All research outputs
#7,486,210
of 22,882,389 outputs
Outputs from Drugs
#1,312
of 3,259 outputs
Outputs of similar age
#119,756
of 315,392 outputs
Outputs of similar age from Drugs
#11
of 29 outputs
Altmetric has tracked 22,882,389 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,259 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,392 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.